JPMorgan hires rival Goldman's executive for its business services unit, memo says-March 2024-www.financetom.com

JPMorgan hires rival Goldman's executive for its business services unit, memo says

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

JPMorgan hires rival Goldman's executive for its business services unit, memo says

Feb 4, 2025 9:35 AM

Feb 4 (Reuters) - JPMorgan & Chase ( JPM ) has hired Goldman Sachs's ( GS ) executive

Jonathan Slaughter to join its business services group, in a bid to expand its coverage in

Europe and the Middle East region, according to a memo seen by Reuters on Tuesday.

Slaughter has been leading Goldman's Business services unit of the North America region. He

will be based out of London, the memo added.

Previous page： Google agrees $36 million fine for anti-competitive deals with Australia telcos Next page： Avadel Pharmaceuticals Gets Orphan Drug Designation for Lumryz to Treat Idiopathic Hypersomnia

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

Avadel Pharmaceuticals Gets Orphan Drug Designation for Lumryz to Treat Idiopathic Hypersomnia

Jun 5, 2025

08:05 AM EDT, 06/05/2025 (MT Newswires) -- Avadel Pharmaceuticals ( AVDL ) said Thursday that Lumryz has been granted Orphan Drug designation by the US Food and Drug Administration to treat idiopathic hypersomnia, a chronic sleep disorder. The company said the designation was granted because Lumryz may be clinically superior to similar approved drugs due to its once-nightly dosing. Lumryz...

Vermilion Energy to Sell U.S. Assets, Provides Updated 2025 Guidance

Jun 5, 2025

08:08 AM EDT, 06/05/2025 (MT Newswires) -- Vermilion Energy ( VET ) on Thursday said it signed a definitive agreement to sell its United States assets for $120 million with net proceeds slated for debt repayment. The assets include approximately 5,500 barrels of oil equivalent per day (boe/d) (81% oil and liquids) of production and approximately 10 million barrels of...

Cellebrite DI to Acquire Corellium for $170 Million Enterprise Value

Jun 5, 2025

08:09 AM EDT, 06/05/2025 (MT Newswires) -- Cellebrite DI ( CLBT ) said Thursday that it has agreed to acquire Corellium, an Arm-based virtualization software, for an enterprise value of $170 million, including $20 million in equity. The company said it may pay an additional $30 million based on performance milestones over the next two years. The deal is expected...